In a new report, Citi analyst Robyn Karnauskas discusses the Gilead Sciences, Inc. GILD/Merck & Co., Inc. MRK patent lawsuit involving Sovaldi. The jury decision on the case is due next week, but a patent expert tells Citi that the issue is far from over.

According to Karnauskas, the dispute may not reach a definitive conclusion for another two to three years.

“Gven GILD’s claim that MRK had ‘unclean hands’ while obtaining information which helped writing of patents in question, this case could take ~2-3 years before reaching conclusion,” he explains.

In the short-term, the patent expert tells Citi that investors need to be prepared for the jury in the current trial to take the easy route and award Merck all of the damages it is seeking. Merck has asked for $2.1 billion in damages, 10 percent ongoing royalties on Sovaldi and 8.9 percent royalties on Harvoni.

Regardless of the jury decision, the expert anticipates that the judge will then hear Gilead’s ‘unclean hands’ argument and could change the verdict and/or the damages. Gilead could also choose…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!